Gyre Therapeutics
GYRE
89 hedge funds and large institutions have $113M invested in Gyre Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 10 closing their positions.
406% more call options, than puts
Call options by funds: $2.92M | Put options by funds: $577K
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
25% more capital invested
Capital invested by funds: $90.7M → $113M (+$22.3M)
10% more funds holding
Funds holding: 81 → 89 (+8)
0.87% more ownership
Funds ownership: 8.67% → 9.54% (+0.87%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$12.9M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$9.85M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.71M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$6.09M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.66M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.55M |
| 3 |
ACM
Altium Capital Management
New York
|
-$1.36M |
| 4 |
Renaissance Technologies
New York
|
-$918K |
| 5 |
Millennium Management
New York
|
-$882K |
GYRE Hedge Fund Activity: Q1 2021 in Review
89 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2021, worth a combined $113M — up 25% from $90.7M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GYRE positions and 10 closed out — a net gain of 8 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $12.9M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.66M sold.
- 89 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2021, up from 81 in Q4 2020.
- Funds reported $113M of Gyre Therapeutics stock for Q1 2021, up 25% quarter-over-quarter.
- 18 funds opened new Gyre Therapeutics positions in Q1 2021 and 10 closed out, a net change of +8 holders.
- The largest Gyre Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $12.9M added.
- The largest Gyre Therapeutics seller in Q1 2021 was AIGH Capital Management, an estimated $2.66M sold.
Based on aggregated 13F filings for Q1 2021.